



2015

Quarterly Report III

Key data Eckert & Ziegler

| | | 01-09/2015 | 01-09/2014 | Change |
|---|-----------|------------|------------|--------|
| Sales | € million | 102.7 | 92.6 | + 11% |
| Return on revenue before tax | % | 13 | 10 | + 32% |
| EBITDA | € million | 19.8 | 15.3 | + 29% |
| EBIT | € million | 13.8 | 10.0 | + 38% |
| EBT | € million | 13.0 | 8.9 | + 47% |
| Net income before other shareholder's interests | € million | 8.5 | 5.4 | + 59% |
| Profit | € million | 9.0 | 5.6 | + 61% |
| Earnings per share (basic) | € | 1.70 | 1.05 | + 61% |
| Operational cash flow | € million | 11.3 | 4.9 | + 132% |
| Depreciation and amortization on non-current assets | € million | 6.0 | 5.3 | + 12% |
| Staff as end of period | Persons | 707 | 716 | - 1% |

Milestones



↑ AWARDS FOR YOUNG NUCLEAR MEDICINE RESEARCHERS

Eckert & Ziegler travel grants are awarded for the eighth time to outstanding young scientists in the field of nuclear medicine at the annual congress of the European Association of Nuclear Medicine (EANM) in Hamburg.



↑ NEW MANAGING DIRECTOR IN RADIATION THERAPY SEGMENT

Dr. Harald Hasselmann (48) has been appointed as the new commercial managing director for sales and finances of Eckert & Ziegler BEBIG. With effect from October 1, 2015 he will be a member of the management team and head the company together with Dr. Edgar Löffler, a medical physicist, who is responsible for the irradiation equipment manufacturer's technical operations.



↑ CERTIFICATE OF RECOGNITION FOR "GOOD CORPORATE CITIZEN"

The American subsidiary Eckert & Ziegler Isotope Products Inc. receives a certificate of recognition as "good corporate citizen" for the year 2014 from the Sanitation Districts of Los Angeles County for complying consistently with all their industrial wastewater discharge requirements.

Business development of the Eckert & Ziegler Group

AVERAGE THIRD QUARTER

Business was moderate at the Eckert & Ziegler Group in the third quarter of 2015. With sales of € 33.7 million and net income of € 1.5 million, the Group generated an average result.

In the first nine months from January to September 2015, sales came in at € 102.7 million. Compared to the same period in the prior year, sales were up by € 10.2 million or 11 %. A majority of this amount, € 8.3 million, is due to the more favorable US dollar / euro exchange rate. The acquisition of the Isotope Products segment in Brazil saw sales climb by € 2.3 million. Organic sales declined slightly by € 0.4 million.

Thanks to the special income reported in the second quarter of 2015 from the disposal of the OctreoPharm Sciences GmbH investment, EBIT improved to € 13.8 million for the first nine months. Profit for the period after taxes and minority interests also increased sharply to € 9.0 million or € 1.70 per share.

The Isotope Products segment benefited the most from the weak euro, while also recording a positive acquisition effect. Organic sales declined by € 2.8 million due to weak sales in the energy sector and radiocarbon dating. Two loss-making areas have been identified in the highly successful segment: the newly acquired Brazilian business and radiocarbon dating. As a result, EBIT for the entire segment fell by € 2.8 million to € 9.6 million.

Sales in the Radiation Therapy segment increased by € 2.0 million to € 21.5 million. Organic sales growth in afterloaders were strong following the launch of the new SagiNova®, but not enough to cover the cost base. Earnings before interest and taxes (EBIT) fell by € 0.5 million to € – 2.9 million. This already includes provisions of € 1.3 million for restructuring measures and consolidation of sites.

The sales of the Radiopharma segment rose by not only the currency effect but also organically, especially in the equipment division and with the gallium generators. The “Other operating income” item includes most of the proceeds arising from the sale of the OctreoPharm investment. As a result, EBIT increased many times over to € 8.7 million.

Price increases meant that the Others segment registered an increase in sales of € 0.6 million to € 5.4 million. EBIT increased significantly by € 1.0 million to € – 1.6 million. This change is largely the result of the balance of a positive and a negative effect: this segment also includes income from the sale of the OctreoPharm investment. A price increase at a key disposal channel led to an increase in provisions for waste materials.

LIQUIDITY

At €9.2 million, gross cash flow, i. e. profit for the period adjusted for non-cash-effective effects, was 17 % below the prior year period, particularly due to the weaker results in the Isotope Products segment.

The reduction in net working capital led to a positive cash flow of €2.2 million and the decline in receivables from customers in the Radiation Therapy segment was the main effect.

Investments in fixed assets declined by €5.1 million to €2.9 million after the completion of the new cyclotron and were mainly restricted to maintenance investments in 2015. The disposal of the OctreoPharm investment led to cash inflow of €5.4 million, with the investment activities resulting in an overall increase in liquidity.

The constant dividend of €0.60 per share led to an unchanged cash outflow of €3.2 million. The amount of loans declined by €2.7 million. Financial holdings increased overall to €29.1 million as of September 30, 2015.

BALANCE SHEET

The balance sheet total as of the end of September 2015 remained nearly unchanged compared to the end of 2014, rising slightly from €187.3 million to €191.4 million. The reasons for the significant changes in the balance sheet were previously described in the statements on cash flow: the offsetting entries to cash inflow include the increase in equity (profit for the period), the decline in the investments valued at equity (disposal of OctreoPharm) and the decline in trade receivables (reduction in receivables in the Radiation Therapy segment). For the planned disposal of a building in the Radiation Therapy segment, €1.0 million was previously reported under “non-current assets available for sale”. As a sale has become more unlikely towards the end of 2015 given the contract negotiations, this item has been reversed and the amount has been reassigned to property, plant and equipment.

EMPLOYEES

The Eckert & Ziegler Group had a total of 707 employees worldwide as of September 30, 2015, 406 of whom worked in Germany. The number of employees has therefore dropped slightly compared to the end of 2014, as the staff reduction in the Radiation Therapy segment had a stronger impact than the recruiting measures in the Radiopharma segment.

OUTLOOK

Sales are expected to rise to over €133 million in 2015, while an improvement in earnings to over €2.00 per share is also targeted. The current US dollar exchange rate is providing major support in achieving this sales target and the operating results achieved thus far also indicate that the targets will be met. Sales are expected to increase slightly to between €137 and €140 million in 2016, assuming exchange rates remain stable. Earnings per share are likely to decline to approximately €1.80 per share in 2016 due to the absence of positive one-off effects.

GROUP STATEMENT OF INCOME

| in € thousand | Quarterly Report III 07-09/2015 | Quarterly Report III 07-09/2014 | 9-monthly Report 01-09/2015 | 9-monthly Report 01-09/2014 |
|---|---------------------------------------|---------------------------------------|-----------------------------------|-----------------------------------|
| Revenues | 33,702 | 30,628 | 102,726 | 92,553 |
| Cost of sales | - 18,334 | - 15,076 | - 56,720 | - 46,138 |
| Gross profit on sales | 15,368 | 15,552 | 46,006 | 46,415 |
| Selling expenses | - 5,851 | - 5,185 | - 18,222 | - 15,694 |
| General and administrative expenses | - 6,453 | - 6,348 | - 19,832 | - 18,649 |
| Other operating income | 368 | 157 | 9,606 | 812 |
| Other operating expenses | - 642 | - 967 | - 3,926 | - 3,202 |
| Profit from operations | 2,790 | 3,209 | 13,632 | 9,682 |
| Results from shares measured at equity | - | - 157 | - 408 | - 295 |
| Results of financial investments measured at fair value | - | - 77 | - | - 142 |
| Other financial results | - 714 | 788 | 567 | 713 |
| Earnings before interest and taxes (EBIT) | 2,076 | 3,763 | 13,791 | 9,958 |
| Interest received | 43 | 46 | 83 | 114 |
| Interest paid | - 319 | - 322 | - 853 | - 1,205 |
| Profit before tax | 1,800 | 3,487 | 13,021 | 8,867 |
| Income tax expense | - 517 | - 1,379 | - 4,514 | - 3,505 |
| Net income | 1,283 | 2,108 | 8,507 | 5,362 |
| Profit/loss attributable to minority interests | 208 | 189 | 465 | 203 |
| Profit attributable to the shareholders of Eckert & Ziegler AG | 1,491 | 2,297 | 8,972 | 5,565 |
| Earnings per share | | | | |
| Basic | 0.28 | 0.43 | 1.70 | 1.05 |
| Diluted | 0.28 | 0.43 | 1.70 | 1.05 |
| Average number of shares in circulation (basic) | 5,288 | 5,288 | 5,288 | 5,288 |
| Average number of shares in circulation (diluted) | 5,288 | 5,288 | 5,288 | 5,288 |

GROUP STATEMENT OF COMPREHENSIVE INCOME

| in € thousand | Quarterly Report III 07-09/2015 | Quarterly Report III 07-09/2014 | 9-monthly Report 01-09/2015 | 9-monthly Report 01-09/2014 |
|--|---------------------------------------|---------------------------------------|-----------------------------------|-----------------------------------|
| Profit for the period | 1,283 | 2,108 | 8,507 | 5,362 |
| Of which attributable to other shareholders | - 208 | - 189 | - 465 | - 203 |
| Of which attributable to shareholders of Eckert & Ziegler AG | 1,491 | 2,297 | 8,972 | 5,565 |
| Items that could subsequently be reclassified into the income statement if certain conditions are met | | | | |
| Adjustment of balancing item from the currency translation of foreign subsidiaries | - 1,494 | 1,964 | 2,386 | 2,260 |
| Amount reposted to income statement | 0 | 0 | 0 | 0 |
| Adjustment of amount recorded in shareholders' equity (Currency translation) | - 1,494 | 1,964 | 2,386 | 2,260 |
| Total of value adjustments recorded in shareholders' equity | - 1,494 | 1,964 | 2,386 | 2,260 |
| Of which attributable to other shareholders | 13 | - 2 | 22 | - 3 |
| Of which attributable to shareholders of Eckert & Ziegler AG | - 1,507 | 1,966 | 2,364 | 2,263 |
| Total from net income and value adjustments recorded in shareholders' equity | - 211 | 4,072 | 10,893 | 7,622 |
| Of which attributable to other shareholders | - 195 | - 191 | - 443 | - 206 |
| Of which attributable to shareholders of Eckert & Ziegler AG | - 16 | 4,263 | 11,336 | 7,828 |

GROUP STATEMENT OF CASH FLOWS

| in € thousand | 9-monthly Report Jan 1, 2015 – Sep 30, 2015 | 9-monthly Report Jan 1, 2014 – Sep 30, 2014 |
|---|--|--|
| Cash flows from operating activities: | | |
| Profit for the period | 8,507 | 5,361 |
| Adjustments for: | | |
| Depreciation and value impairments | 5,981 | 5,333 |
| Non-cash release of deferred income from grants | – 99 | – 54 |
| Gains (–)/losses on the disposal of non-current assets | 8 | – 4 |
| Gains on the sale of shares measured at equity | – 8,785 | – |
| Change in the non-current provisions, other non-current liabilities | 3,242 | 1,073 |
| Change in other non-current assets and receivables | 485 | 5 |
| Miscellaneous | – 186 | – 751 |
| Changes in current assets and liabilities: | | |
| Receivables | 4,150 | 2,386 |
| Inventories | 588 | – 3,874 |
| Accruals, other current assets | – 486 | – 86 |
| Change in the current liabilities and provisions | – 2,089 | – 4,501 |
| Cash inflows generated from operating activities | 11,316 | 4,888 |
| Cash flows from investing activities: | | |
| Purchase (–)/sale of non-current assets | – 2,883 | – 8,019 |
| Acquisitions of consolidated enterprises | – 601 | – 1,017 |
| Sale of shares measured at equity | 5,366 | – |
| Cash inflows / outflows from investment activity | 1,882 | – 9,036 |
| Cash flows from financing activities: | | |
| Paid dividends | – 3,173 | – 3,173 |
| Distribution of shares of third parties | – 538 | – 342 |
| Change in long-term borrowing | – 2,304 | – 3,356 |
| Change in short-term borrowing | – 395 | 1,021 |
| Aquisition of shares of consolidated companies | – 100 | – 20 |
| Cash outflows from financing activities | – 6,510 | – 5,870 |
| Effect of exchange rates on cash and cash equivalents | 567 | 773 |
| Increase / reduction in cash and cash equivalents | 7,255 | – 9,245 |
| Cash and cash equivalents at beginning of period | 21,824 | 29,414 |
| Cash and cash equivalents at end of period | 29,079 | 20,169 |

GROUP BALANCE SHEETS

in € thousand

| | Sep 30, 2015 | Dec 31, 2014 |
|---|----------------|----------------|
| Assets | | |
| Non current assets | | |
| Goodwill | 39,666 | 38,321 |
| Other intangible assets | 15,634 | 17,297 |
| Property, plant and equipment | 36,280 | 36,119 |
| Investments valued according to the equity method | 2,702 | 5,323 |
| Trade accounts receivable | – | 368 |
| Deferred tax | 9,399 | 9,465 |
| Other non-current assets | 5,724 | 2,501 |
| Total non-current assets | 109,405 | 109,394 |
| Current assets | | |
| Cash and cash equivalents | 29,079 | 21,824 |
| Trade accounts receivable | 18,904 | 23,401 |
| Inventories | 24,470 | 24,322 |
| Other current assets | 9,590 | 7,426 |
| Assets held for sale | – | 962 |
| Total current assets | 82,043 | 77,935 |
| Total assets | 191,448 | 187,329 |
| Equity and liabilities | | |
| Capital and reserves | | |
| Subscribed capital | 5,293 | 5,293 |
| Capital reserves | 53,500 | 53,500 |
| Retained earnings | 37,935 | 32,136 |
| Other reserves | 38 | – 2,326 |
| Own shares | – 27 | – 27 |
| Portion of equity attributable to the shareholders of Eckert & Ziegler AG | 96,739 | 88,576 |
| Minority interests | 4,933 | 5,914 |
| Total shareholders' equity | 101,672 | 94,490 |
| Non-current liabilities | | |
| Long-term borrowings | 5,949 | 7,279 |
| Deferred income from grants and other deferred income | 1,598 | 680 |
| Deferred tax | 3,751 | 2,728 |
| Retirement benefit obligations | 11,072 | 11,094 |
| Other provisions | 26,272 | 23,637 |
| Other non-current liabilities | 4,371 | 4,632 |
| Total non current liabilities | 53,013 | 50,050 |
| Current liabilities | | |
| Short-term borrowings | 10,122 | 11,426 |
| Trade accounts payable | 5,422 | 8,220 |
| Advance payments received | 35 | 3,090 |
| Deferred income from grants and other deferred income | 217 | 117 |
| Current tax payable | 2,624 | 2,142 |
| Current tax payable | 3,600 | 3,600 |
| Other current liabilities | 14,743 | 14,194 |
| Total current liabilities | 36,763 | 42,789 |
| Total equity and liabilities | 191,448 | 187,329 |

STATEMENTS OF SHAREHOLDERS' EQUITY

| | Subscribed capital | | | | Cumulative other equity items | | | | | | |
|--|--------------------|-----------------------------|-------------------------------|---------------------------------|---|--|---|--------------------------|--|-------------------------------|--|
| | Number Piece | Nominal value € thsd. | Capital reserve € thsd. | Retained reserves € thsd. | Unrealized profit securities € thsd. | Unrealized profit pension commit- ments € thsd. | Foreign currency exchange differences € thsd. | Own shares € thsd. | Equity attributable to share- holders' equity € thsd. | Minority shares € thsd. | Group share- holders' equity € thsd. |
| As of January 1, 2014 | 5,292,983 | 5,293 | 53,500 | 28,534 | 2 | - 833 | - 2,977 | - 27 | 83,492 | 6,773 | 90,265 |
| Total of expenditures and income directly entered in equity | 0 | 0 | 0 | 0 | - 2 | - 1,832 | 3,316 | 0 | 1,482 | - 13 | 1,469 |
| Net profit for the year | | | | 6,775 | | | | | 6,775 | - 278 | 6,497 |
| Total income for the period | 0 | 0 | 0 | 6,775 | - 2 | - 1,832 | 3,316 | 0 | 8,257 | - 291 | 7,966 |
| Dividends paid | | | | - 3,173 | | | | | - 3,173 | - 568 | - 3,741 |
| As of December 31, 2014 | 5,292,983 | 5,293 | 53,500 | 32,136 | 0 | - 2,665 | 339 | - 27 | 88,576 | 5,914 | 94,490 |
| As of January 1, 2015 | 5,292,983 | 5,293 | 53,500 | 32,136 | 0 | - 2,665 | 339 | - 27 | 88,576 | 5,914 | 94,490 |
| Total of expenditures and income directly entered in equity | 0 | 0 | 0 | 0 | 0 | 0 | 2,364 | 0 | 2,364 | 22 | 2,386 |
| Net profit for the year | | | | 8,972 | | | | | 8,972 | - 465 | 8,507 |
| Total income for the period | 0 | 0 | 0 | 8,972 | 0 | 0 | 2,364 | 0 | 11,336 | - 443 | 10,893 |
| Dividends paid | | | | - 3,173 | | | | | - 3,173 | - 538 | - 3,711 |
| As of September 30, 2015 | 5,292,983 | 5,293 | 53,500 | 37,935 | 0 | - 2,665 | 2,703 | - 27 | 96,739 | 4,933 | 101,672 |

SEGMENTAL REPORT

| | Isotope Products | | Radiation Therapy | | Radiopharma | | Others | | Elimination | | Total | |
|--|------------------|------------|-------------------|------------|-------------|------------|------------|------------|-------------|------------|------------|------------|
| in € thousand | 01-09/2015 | 01-09/2014 | 01-09/2015 | 01-09/2014 | 01-09/2015 | 01-09/2014 | 01-09/2015 | 01-09/2014 | 01-09/2015 | 01-09/2014 | 01-09/2015 | 01-09/2014 |
| Sales to external customers | 49,579 | 44,166 | 21,541 | 19,549 | 26,233 | 24,107 | 5,373 | 4,731 | 0 | 0 | 102,726 | 92,553 |
| Sales to other segments | 1,979 | 1,414 | 147 | 129 | 21 | 49 | 4,534 | 3,769 | - 6,682 | - 5,361 | 0 | 0 |
| Total segment sales | 51,558 | 45,580 | 21,688 | 19,678 | 26,254 | 24,156 | 9,907 | 8,500 | - 6,682 | - 5,361 | 102,726 | 92,553 |
| Segment profit before interest and profit taxes (EBIT) | 9,575 | 12,387 | - 2,908 | - 2,388 | 8,745 | 2,548 | - 1,621 | - 2,589 | 0 | 0 | 13,791 | 9,958 |
| Interest expenses and revenues | - 47 | - 50 | - 238 | - 395 | - 910 | - 910 | 425 | 264 | 0 | 0 | - 770 | - 1,091 |
| Income tax expense | - 3,567 | - 3,803 | - 739 | 162 | - 568 | - 710 | 360 | 846 | 0 | 0 | - 4,514 | - 3,505 |
| Profit before minority interests | 5,961 | 8,534 | - 3,885 | - 2,621 | 7,267 | 928 | - 836 | - 1,479 | 0 | 0 | 8,507 | 5,362 |

SEGMENTAL REPORT

| | Isotope Products | | Radiation Therapy | | Radiopharma | | Others | | Total | |
|---|------------------|------------|-------------------|------------|-------------|------------|------------|------------|------------|------------|
| in € thousand | 01-09/2015 | 01-09/2014 | 01-09/2015 | 01-09/2014 | 01-09/2015 | 01-09/2014 | 01-09/2015 | 01-09/2014 | 01-09/2015 | 01-09/2014 |
| Segmental assets | 91,213 | 101,813 | 52,291 | 55,122 | 38,481 | 35,827 | 94,989 | 93,616 | 276,974 | 286,378 |
| Elimination of inter-segmental shares, equity investments and receivables | | | | | | | | | - 85,526 | - 105,808 |
| Consolidated total assets | | | | | | | | | 191,448 | 180,570 |
| Segmental liabilities | - 39,691 | - 43,397 | - 24,763 | - 23,106 | - 29,901 | - 34,443 | - 16,391 | - 5,954 | - 110,746 | - 106,900 |
| Elimination of intersegmental liabilities | | | | | | | | | 20,970 | 21,065 |
| Consolidated liabilities | | | | | | | | | - 89,776 | - 85,835 |
| Investments (without acquisitions) | 1,250 | 3,241 | 416 | 1,486 | 873 | 2,131 | 344 | 1,161 | 2,883 | 8,019 |
| Depreciation | - 2,178 | - 1,713 | - 1,635 | - 1,713 | - 1,405 | - 1,228 | - 763 | - 679 | - 5,981 | - 5,333 |
| Non-cash income (+) / expenses (-) | 100 | 417 | - 480 | - 271 | 4,772 | - 450 | 943 | 35 | 5,335 | - 269 |

SALES BY REGIONS

| | 01–09/2015 | | 01–09/2014 | |
|----------------|------------|-----|------------|-----|
| | € million | % | € million | % |
| Europe | 49.1 | 48 | 49.0 | 53 |
| North America | 35.8 | 35 | 30.8 | 33 |
| Asia / Pacific | 10.6 | 10 | 9.1 | 10 |
| Others | 7.2 | 7 | 3.7 | 4 |
| Total | 102.7 | 100 | 92.6 | 100 |

Notes to the interim financial statements

1. GENERAL INFORMATION

These unaudited interim financial statements as of September 30, 2015 contain the financial statements of Eckert & Ziegler Strahlen- und Medizintechnik AG and its subsidiaries (hereinafter referred to as “Eckert & Ziegler AG”).

2. ACCOUNT AND VALUATION METHODS

As with the annual financial statements for 2014, the consolidated financial statements (interim financial statements) of Eckert & Ziegler AG as of September 30, 2015 have been prepared in accordance with International Financial Reporting Standards (IFRS). All standards of the International Accounting Standards Board (IASB), London, applicable in the EU at the reporting date, as well as the relevant interpretations of the International Financial Reporting Interpretations Committee (IFRIC) and the Standing Interpretations Committee (SIC) have been taken into account. The accounting and valuation methods explained in the notes to the annual financial statements for 2014 have been applied unchanged.

When preparing the consolidated financial statements in accordance with IFRS, it is necessary to make estimates and assumptions that impact the amount and disclosure of recognized assets and liabilities, revenues and expenses. Actual amounts may differ from the estimates. Significant assumptions and estimates are made concerning useful lives, income achievable from property, plant and equipment, recoverability of receivables and the accounting and measurement of provisions.

This interim report includes all information and adjustments required to provide a true and fair view of the net assets, financial position and results of operations of Eckert & Ziegler AG as of the reporting date. The interim results for the current fiscal year do not necessarily allow conclusions to be drawn about the development of future earnings.

3. SCOPE OF CONSOLIDATION

The consolidated financial statements of Eckert & Ziegler AG include all companies where Eckert & Ziegler AG is able, either indirectly or directly, to determine the company's financial and business policies (control concept).

Acquisitions and sales of companies

Please refer to the explanations given in section 4 for details on the acquisitions and sales of companies.

4. LIMITED COMPARABILITY OF THE CONSOLIDATED FINANCIAL STATEMENTS WITH THE PRIOR YEAR

The Isotope business unit of REM Indústria e Comércio Ltda. (REM), which is based in São Paulo, Brazil, was acquired effective September 1, 2014.

These had a material impact on the Group's net assets and results of operations as against the first nine months of 2014, impairing the comparability of the consolidated report with the prior year.

5. CURRENCY TRANSLATION

The financial statements of companies outside the European Monetary Union are translated pursuant to the functional currency concept. The following exchange rates were used for the currency translation:

| Country | Currency | Exchange rate Sep 30, 2015 | Exchange rate Dec 31, 2014 | Average rate Jan 1–Sep 30, 2015 | Average rate Jan 1–Sep 30, 2014 |
|----------------|----------|-------------------------------|-------------------------------|------------------------------------|------------------------------------|
| USA | USD | 1.1203 | 1.2141 | 1.1144 | 1.3518 |
| Czech Republic | CZK | 27.187 | 27.735 | 27.3547 | 27.5067 |
| Great Britain | GBP | 0.7385 | 0.7789 | 0.7271 | 0.8206 |
| Poland | PLN | 4.2448 | 4.2732 | 4.1571 | 4.1723 |
| Russia | RUB | 73.2416 | 72.337 | 66.5974 | 47.9569 |
| Brazil | BRL | 4.4808 | 3.2207 | 3.5257 | 3.0924 |


6. OWN SHARES

Eckert & Ziegler AG held 4,818 own shares as of September 30, 2015. This equates to a 0.1 % share of the Company's subscribed capital.

7. MATERIAL TRANSACTIONS WITH RELATED PARTIES

Please refer to the consolidated financial statements as of December 31, 2014 for details on material transactions with related parties.

Berlin, November 5, 2015



Dr. Andreas Eckert
Chairman of the Executive Board



Dr. Edgar Löffler
Member of the Executive Board



Dr. André Heß
Member of the Executive Board

Financial calendar

| | |
|----------------------|--|
| November 23/24, 2015 | German Equity Forum in Frankfurt |
| March 23, 2016 | Annual Report 2015 |
| May 10, 2016 | Quarterly Report I/2016 |
| June 8, 2016 | Annual Shareholder Meeting in Berlin |
| August 2, 2016 | Quarterly Report II/2016 |
| November 3, 2016 | Quarterly Report III/2016 (subject to change) |

Contact

Eckert & Ziegler
Strahlen- und Medizintechnik AG

Robert-Rössle-Straße 10
13125 Berlin, Germany
www.ezag.com

Karolin Riehle
Investor Relations

Phone + 49 30 94 10 84 – 0
Fax + 49 30 94 10 84 – 112
info@ezag.de

Imprint

PUBLISHER

Eckert & Ziegler
Strahlen- und Medizintechnik AG

LAYOUT

Ligaturas, Berlin

PHOTO

Cover: istockphoto.com
Page 3 bottom right: fotolia.de
Eckert & Ziegler archives